PE38-conjugated anti-CD30 immunotoxin (NCI)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePE38-conjugated anti-CD30 immunotoxin (NCI)

Drug Alias Nameanti-CD30 dsFV-PE38 immunotoxin (NCI)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Toxin

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors

TargetsTumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsHematologic DiseasesLymphoma, Large-Cell, AnaplasticHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsHematologic DiseasesLymphoma, Large-Cell, AnaplasticHodgkin Disease

Other Information

ATC CodeN/A